Sees cost-savings of approximately $50M in 1H 2025 from previously announced $100M annualized cost-savings initiatives; $30M-$50M of additional cost-savings in 2025; Positive adjusted free cash flow with 25%-30% of adjusted EBITDA conversion; Interest expense of $158M-$162M; Capital expenditures of $160M-$170M, excluding instruments under reagent rental agreements and integration costs. Comments taken from investor presentation slides.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL: